These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26446328)

  • 1. Comparison of solifenacin and fesoterodine in treatment of overactive bladder.
    Ercan Ö; Köstü B; Bakacak M; Aytaç-Tohma Y; Çoşkun B; Avcı F; Efe E
    Saudi Med J; 2015 Oct; 36(10):1181-5. PubMed ID: 26446328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
    Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
    J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of health care resources and associated costs in non-institutionalized vulnerable elders with overactive bladder treated with antimuscarinic agents in the usual medical practice.
    Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Aguado-Jodar A; Ruíz-Torrejón A
    Actas Urol Esp; 2014 Oct; 38(8):530-7. PubMed ID: 24630426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Loss of Work Productivity in Patients with Overactive Bladder Treated with Antimuscarinics in Spain: Study in Routine Clinical Practice Conditions.
    Sicras-Mainar A; Navarro-Artieda R; Ruiz-Torrejón A; Sáez-Zafra M; Coll-de Tuero G
    Clin Drug Investig; 2015 Dec; 35(12):795-805. PubMed ID: 26464261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study.
    Vecchioli Scaldazza C; Morosetti C
    Urol Int; 2016; 97(3):325-329. PubMed ID: 27092789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overactive bladder symptom score to evaluate efficacy of solifenacin for the treatment of overactive bladder symptoms.
    Liu M; Wang J; Yang Y; An R; Wen J; Guan Z; Zheng S; Wang D; Song B; Liao L; Guo H; Xiao J; Sun Y; Shen Z; Kong C; He D; Huang Y; Wang X; Zhang X; Li H; Huang J; Zhao X; Zeng P; Song X; Ye Z
    Chin Med J (Engl); 2014; 127(2):261-5. PubMed ID: 24438613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women.
    Chughtai B; Forde JC; Buck J; Asfaw T; Lee R; Te AE; Kaplan SA
    Post Reprod Health; 2016 Mar; 22(1):34-40. PubMed ID: 26883688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of combined solifenacin and aclatonium in preventing dry mouth in patients with overactive bladder.
    Park HK; Kim HG; Yang DY; Choi WS; Paick SH; Chung H; Yang SK
    Low Urin Tract Symptoms; 2019 Jan; 11(1):56-60. PubMed ID: 28967201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
    Ho CH; Chang TC; Lin HH; Liu SP; Huang KH; Yu HJ
    J Formos Med Assoc; 2010 Oct; 109(10):702-8. PubMed ID: 20970066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence and concomitant medication in patients with overactive bladder treated with antimuscarinic agents in primary care. An observational baseline study.
    Sicras-Mainar A; Navarro-Artieda R; Ruiz-Torrejón A; Sáez-Zafra M; Coll-de Tuero G
    Actas Urol Esp; 2016 Mar; 40(2):96-101. PubMed ID: 26556482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Daytime or Nighttime Dosing with Solifenacin for Overactive Bladder with Nocturia: Impact on Nocturia and Sleep Quality.
    Kwon T; Oh TH; Choi S; Cho WY; Min K; Lee JZ; Moon KH
    J Korean Med Sci; 2017 Sep; 32(9):1491-1495. PubMed ID: 28776345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of solifenacin succinate tablets versus solifenacin succinate tablets with local estrogen for the treatment of overactive bladder in postmenopausal women--a multicenter, randomized, open-label, controlled comparison study.
    Jiang F; Zhu L; Xu T; Gong MY; Huang YL; Li HF; Wang JJ; Tong XW; Cheng XX; Bai WP; Li X; Xu XX; Xu HC
    Menopause; 2016 Apr; 23(4):451-7. PubMed ID: 26757270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.
    Sánchez-Ballester F; Miranda P; Lizarraga I; Rejas J; Arumi D
    Actas Urol Esp; 2014 Apr; 38(3):156-63. PubMed ID: 24119382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.